17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

LINONG JI; WEIHONG SONG; HUI FANG; WEI LI; JIANLIN GENG; YAN CHENG XU; YANGANG WANG; LIAN GUO; HANQING CAI; TAO YANG; HONG-MEI LI; GANGYI YANG; QIFU LI; KUANZHI LIU; SHUYING LI; YANJUN LIU; FUYAN SHI; XIN SHENG LI; XIN GAO; QIUHE JI; HAOMING TIAN; QING SU; ZHIGUANG ZHOU; WENBO WANG; ZUNHAI ZHOU; XUEJUN LI; YAN CHENG XU; ZHIQIANG NING; XIANPING LU; WEIPING JIA

doi:10.2337/db19-17-or

17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

Diabetes ◽

10.2337/db19-17-or ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 17-OR ◽

Cited By ~ 1

Author(s):

LINONG JI ◽

WEIHONG SONG ◽

HUI FANG ◽

WEI LI ◽

JIANLIN GENG ◽

...

Keyword(s):

Type 2 Diabetes ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Superiority Trial

Download Full-text

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3437798 ◽

2019 ◽

Author(s):

Linong Ji ◽

Weihong Song ◽

Hui Fang ◽

Wei Li ◽

Jianlin Geng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Peroxisome Proliferator ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Double Blind Placebo ◽

Superiority Trial

Download Full-text

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

Journal of Diabetes ◽

10.1111/1753-0407.12425 ◽

2016 ◽

Vol 9 (4) ◽

pp. 386-395 ◽

Cited By ~ 10

Author(s):

Changyu Pan ◽

Ping Han ◽

Qiuhe Ji ◽

Chengjiang Li ◽

Juming Lu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Hong Kong ◽

Mainland China ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

Science Bulletin ◽

10.1016/j.scib.2021.03.019 ◽

2021 ◽

Author(s):

Linong Ji ◽

Weihong Song ◽

Hui Fang ◽

Wei Li ◽

Jianlin Geng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Peroxisome Proliferator ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Endocrinology Diabetes & Metabolism ◽

10.1002/edm2.222 ◽

2021 ◽

Author(s):

Linong Ji ◽

Ling Li ◽

Jianhua Ma ◽

Xuefeng Li ◽

Dongmei Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes ( TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

Diabetes Obesity and Metabolism ◽

10.1111/dom.14642 ◽

2022 ◽

Author(s):

Caroline Reilhac ◽

Julie Dubourg ◽

Carole Thang ◽

Jean‐Marie Grouin ◽

Pascale Fouqueray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Extension Period

Download Full-text

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

Current Medical Research and Opinion ◽

10.1185/03007995.2014.912983 ◽

2014 ◽

Vol 30 (7) ◽

pp. 1245-1255 ◽

Cited By ~ 64

Author(s):

Yutaka Seino ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Michito Ubukata ◽

Soichi Sakai ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text